Despite all these findings, most of the studies in NB have been focused on the role of N-MYC, instead of c-Myc, in the regulation of p53 and TAp73, as MYCN amplification is a gold standard marker routinely used in clinic for risk assessment of NB. The gene discussed is MYC; the disease is neuroblastoma.